Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary Becker Biologics has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant), granting approval to conduct clinical trials for preventing influenza caused by vaccine-related strains of influenza virus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.